FDA's New Rules for Cheaper Copycat Drugs: Biosimilars Get a Guidance Boost
Published Date: 9/9/2025
Notice
Summary
The FDA just released final advice to help drug makers prove their new protein medicines are just as good as the originals. This update affects companies developing biosimilars by clarifying how to compare products and what info to include in their applications. It aims to speed up approval and save money by making the process clearer and more reliable.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clarifies how to show biosimilarity
The FDA released final guidance explaining how drug makers should design and evaluate comparative analytical studies to show a therapeutic protein is biosimilar to a reference product licensed under the Public Health Service Act. The guidance finalizes and replaces the draft guidance issued May 22, 2019 and the prior final guidance issued April 30, 2015.
Specifies CMC info for biosimilar applications
The final guidance provides recommendations to sponsors on the scientific and technical information to include in the chemistry, manufacturing, and controls (CMC) section of a marketing application submitted under the Public Health Service Act. Sponsors developing therapeutic protein biosimilars should follow these CMC recommendations when preparing their applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-17222, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Product Establishment Registration and Listing
The FDA wants to keep track of tobacco product makers by updating their registration and listing rules. This affects businesses that make or sell tobacco products, who’ll need to share info with the FDA. The government is checking the paperwork to make sure it’s fair and won’t cost too much time or money.
Next: 2025-17228, Cheniere Corpus Christi Pipeline, LP; Notice of Request for Extension of Time
Cheniere Corpus Christi Pipeline, LP is asking for more time—until the end of 2029—to finish building their Stage 3 Pipeline Project in Texas. This project includes a big pipeline and some powerful compressor machines to help move gas. The delay means they need extra time to complete important parts, but they’ve already started and even put some equipment to work.